Paolo Ghia, MD, PhD, from the San Raffaele Scientific Institute, Milano, Italy talks to us about the importance of assessing the quality of life in patients with chronic lymphocytic leukemia (CLL) who are treated with novel drugs rather than chemotherapy. A questionnaire, described by Prof. Ghia, that is specialised for CLL patients, is currently aiming to address how the quality of life of patients treated with novel drugs changes over time and he hopes that this study will validate how the duration of treatment correlates with the quality of life of a CLL patient. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.